Filters
Other countries
Results: 1 to 14 of 14
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Invitae Expanded Renal Disease Panel Invitae United States | 693 | 388 |
|
Invitae United States | 2 | 1 |
|
CHRNA3 - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany | 2 | 1 |
|
Centogene AG - the Rare Disease Company Germany | 498 | 498 |
|
Centogene AG - the Rare Disease Company Germany | 499 | 499 |
|
Lung cancer susceptibility 2, 612052 (CHRNA5 gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Lung cancer susceptibility 2, 612052 (CHRNA3 gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Congenital Abnormalities of the Kidney and Urinary Tract (CAKUT) Panel PreventionGenetics, part of Exact Sciences United States | 82 | 77 |
|
Rett syndrome and other related syndromes. 34-gene NGS panel. Genologica Medica Spain | 58 | 34 |
|
Neuromuscular Channelopathies , Panel Massive Sequencing (NGS) 44 Genes Reference Laboratory Genetics Spain | 60 | 44 |
|
Fulgent Genetics United States | 1 | 1 |
|
Fulgent Genetics United States | 1 | 1 |
|
Fulgent Genetics United States | 5129 | 4672 |
|
Results: 1 to 14 of 14
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.